Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Tuberous Sclerosis 6Seizures 5Marijuana Abuse 3Lennox Gastaut Syndrome 3Epilepsies, Myoclonic 3Colonic Neoplasms 3Breast Neoplasms 3Sturge-Weber Syndrome 2Neoplasms 2Nausea 2Glioblastoma 2Anxiety Disorders 2Vomiting 1Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Parasomnias 1Pancreatic Neoplasms 1Pain 1Multiple Myeloma 1Liver Neoplasms 1Liver Cirrhosis 1Gallbladder Neoplasms 1Epilepsy 1Dysgeusia 1Drug Resistant Epilepsy 1Colorectal Neoplasms 1

Interventions

Cannabidiol 2Timolol 1Sirolimus 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sturge-Weber Syndrome × Cannabidiol × Clear all
NCT04447846 2023-05-25

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 2 Completed
11 enrolled 25 charts

Sturge-Weber Syndrome, Cognitive Dysfunction

NCT02332655 2022-03-02

Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 1/2 Completed
5 enrolled 8 charts

Drug Resistant Epilepsy, Sturge-Weber Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡